Which is better, HALO or NPCE?

On the Buffett-Fit framework, Halozyme Therapeutics, Inc. (HALO) currently grades higher than NPCE — 69/100 (B grade) vs 30/100 (F). That said, "better" depends on which framework you trust — HALO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Joel Greenblatt, Charlie Munger, and Terry Smith; NPCE wins on Peter Lynch. The full pillar breakdown is on this page.

Should I buy HALO or NPCE?

This page is an educational comparison, not investment advice. Both HALO and NPCE are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is HALO better than NPCE for value investing?

On the Buffett-style value-investing framework, HALO currently grades higher — 69/100 vs 30/100, a 39-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between HALO and NPCE on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). HALO currently scores 69/100 (B grade); NPCE scores 30/100 (F grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, HALO or NPCE?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. HALO and NPCE are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, HALO or NPCE?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are HALO and NPCE both Healthcare stocks?

Yes — both Halozyme Therapeutics, Inc. (HALO) and NeuroPace, Inc. (NPCE) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this HALO vs NPCE comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Halozyme Therapeutics

NeuroPace

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

HALO

Market cap

$8.41B

Sector

Healthcare

NPCE

NeuroPace

Market cap

$536.42M

Sector

Healthcare

Overall winner

Halozyme Therapeutics HALO

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	HALO	NPCE	Winner
Warren Buffett	69B	30F	HALO
Benjamin Graham	73B	55C	HALO
Philip Fisher	55C	42D	HALO
Peter Lynch	43D	66B	NPCE
Joel Greenblatt	30F	0F	HALO
Charlie Munger	70B	28F	HALO
Terry Smith	74B	24F	HALO

Side-by-side metrics

Metric	HALO	NPCE
Market cap	$8.41B	$536.42M
P/E (TTM)	24.0x	-
EV/EBIT	10.2x	-
ROIC (TTM)	23.65%	-19.74%
Gross margin	81.24%	78.29%
Net margin	23.13%	-14.95%
Revenue CAGR 5y	33.23%	21.97%
EPS CAGR 5y	-1.98%	-
Debt / Equity	1.0x	4.9x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

HALO leads on

ROIC (TTM)23.65%vs -19.74%+183%
Net margin23.13%vs -14.95%+165%
Market cap$8.41Bvs $536.42M+94%
Debt / Equity1.0xvs 4.9x+81%

NPCE leads on

P/E (TTM)-vs 24.0x+167%
EV/EBIT-vs 10.2x+128%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Halozyme Therapeutics

NeuroPace

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like HALO

More like NPCE

Related on invest-like

Key terms in this analysis